Search filters

List of works by Andrew Belch

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.

scientific article

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

scientific article published on 19 August 2019

Active idiotypic vaccination versus control immunotherapy for follicular lymphoma

scientific article

Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients

scientific article published on 13 October 2020

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

scholarly article by Athanasios Dimopoulos et al published 20 September 2018 in Haematologica

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

scientific article published on 2 June 2015

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth

scientific article

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

scientific article published on 17 November 2017

Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group

scientific article

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

scientific article

Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma

scientific article published on 25 November 2014

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

scientific article published on September 2014

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

scientific article published on 19 March 2009

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

scientific article published on 13 January 2014

Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial

scientific article published on 6 June 2015

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

scientific article

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial

scientific article published on 20 June 2016

Paulina is supported by:

About Paulina

Help